drugset
drugset / Trial / NCT05029960

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

NCT05029960 ↗

Phase 0 Terminated 3 enrolled University of Rochester
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the study medication, brivaracetam, is tolerable and safe for patients with brain tumors.

Timeline

Start
2022-05-17
Primary completion
2024-05-09
Completion
2024-05-09

Outcome

Outcome not reported

Stopped (Enrollment): “lack of enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 50 mg —

Indications

brain neoplasm